Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press28710.17650/1994-4098-2009-0-1-2-34-41PHARMACOTHERAPYГИНЕКОЛОГИЯ. ФАРМАКОТЕРАПИЯADJUVANT GOSERELIN IN PRE-MENOPAUSAL PATIENTS WITH EARLY BREAST CANCER: RESULTS FROM THE ZIPP STUDYАДЪЮВАНТНАЯ ТЕРАПИЯ ГОЗЕРЕЛИНОМ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ НА РАННИХ СТАДИЯХ У ПАЦИЕНТОК В ПРЕМЕНОПАУЗЕ: РЕЗУЛЬТАТЫ ПРОГРАММЫ ZIPPBaumM.
United Kingdom
HackshawA.
United Kingdom
HoughtonaJ.
United Kingdom
RutqvistL. E.
Sweden
FornanderT.
Sweden
NordenskjoldB.
Sweden
NicolucciA.
Italy
SainsburyaR.SainsburyR.
United Kingdom
r.sainsbury@ucl.ac.ukDepartment of Surgery, University College London, Institute of Surgical Studies, 67—73 Riding House Street, Charles Bell House, London W1W 7EJCancer Research UK & UCL Cancer Trials Centre, University College LondonZIPP International Collaborators' GroupStockholm Breast Cancer Study GroupSouth-East Sweden Breast Cancer GroupGruppo Interdisciplinare Valutazione Interventi in Oncologia010520091-2344101092014010920142009https://ojrs.abvpress.ru/ojrs/article/view/287

The Zoladex In Pre-menopausal Patients (ZIPP) study was designed to determine whether addition of goserelin (‘Zoladex’) and/or tamoxifen to adjuvant therapy (radiotherapy and/or chemotherapy), provided benefit to pre- or peri-menopausal women with operable, early breast cancer.

Цель исследования — определить преимущество применения гозерелина в сочетании с тамоксифеном или без него как дополнение к стандартной адъювантной терапии у пациенток с диагностированным раком молочной железы (РМЖ) в пременопаузе.

Ovarian ablationGoserelinAdjuvantChemotherapyEarly breast cancerPre-menopausalOvarian ablationGoserelinAdjuvantChemotherapyEarly breast cancerPre-menopausal1. Kelsey J.L., Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health 1996;17:47—67.Kelsey J.L., Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health 1996;17:47—67.2. Hankinson S.E., Willett W.C., Colditz G.A. et al. Circulating concen- trations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393—6.Hankinson S.E., Willett W.C., Colditz G.A. et al. Circulating concen- trations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393—6.3. Poikonen P., Saarto T., Elomaa I. et al. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast can- cer patients. Eur J Cancer 2000;36:43—8.Poikonen P., Saarto T., Elomaa I. et al. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast can- cer patients. Eur J Cancer 2000;36:43—8.4. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the ran- domised trials. Lancet 1996;348:1189—96.Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the ran- domised trials. Lancet 1996;348:1189—96.5. Nystedt M., Berglund G., Bolund C. et al. Side-effects of adjuvant endocrine treatment in pre-menopausal breast can- cer patients: a prospective randomised study. J Clin Oncol 2003;21:1836—44.Nystedt M., Berglund G., Bolund C. et al. Side-effects of adjuvant endocrine treatment in pre-menopausal breast can- cer patients: a prospective randomised study. J Clin Oncol 2003;21:1836—44.6. International Breast Cancer Study Group (IBCSG). Adjuvant chemothera- py followed by goserelin versus either modality alone for pre-menopausal lymph nodenegative breast cancer: a ran- domised trial. JNCI 2003;95:1833—46.International Breast Cancer Study Group (IBCSG). Adjuvant chemothera- py followed by goserelin versus either modality alone for pre-menopausal lymph nodenegative breast cancer: a ran- domised trial. JNCI 2003;95:1833—46.7. Kaufmann M., Jonat W., Blamey R. et al. on behalf of the Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists' Group. Eur J Cancer 2003;39:1711—7.Kaufmann M., Jonat W., Blamey R. et al. on behalf of the Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists' Group. Eur J Cancer 2003;39:1711—7.8. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the ran- domised trials. Lancet 1998;351:1451—67.Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the ran- domised trials. Lancet 1998;351:1451—67.9. Pagani O., O'Neill A., Castiglione M. et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in pre- menopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998;34:632—40.Pagani O., O'Neill A., Castiglione M. et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in pre- menopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998;34:632—40.10. Poikonen P., Saarto T., Elomaa I. et al. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in pre-menopausal node-positive breast cancer patients. Eur J Cancer 2000;36:43—8.Poikonen P., Saarto T., Elomaa I. et al. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in pre-menopausal node-positive breast cancer patients. Eur J Cancer 2000;36:43—8.11. Davidson N.E., O'Neill A.M., Vukov A.M. et al. Chemoendocrine ther- apy for premenopausal women with axil- lary lymph nodepositive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 2005;23(25):5973—82.Davidson N.E., O'Neill A.M., Vukov A.M. et al. Chemoendocrine ther- apy for premenopausal women with axil- lary lymph nodepositive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 2005;23(25):5973—82.12. Goldhirsch A., Glick J.H., Gelber R.D. et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. sev- enth international conference on adju- vant therapy of primary breast cancer. J Clin Oncol 2001;19:3817—27.Goldhirsch A., Glick J.H., Gelber R.D. et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. sev- enth international conference on adju- vant therapy of primary breast cancer. J Clin Oncol 2001;19:3817—27.13. NIH Consensus Development Panel. J Natl Cancer Inst 2001;93:979—89.NIH Consensus Development Panel. J Natl Cancer Inst 2001;93:979—89.